# Navigating the Healthcare Innovation Cycle



#### Introduction:

CIMIT's 20<sup>+</sup> years of experience in facilitating more than 600 projects is that innovation in Healthcare is a learnable, teachable process, which it has termed the "Healthcare Innovation Cycle". By following the process, teams can put the experiences of others in navigating the journey of healthcare innovation into action and help avoid preventable mistakes that can derail even the most promising of ideas. The result is improved speed and chances that promising innovations actually reach patients and improve care.

#### Healthcare Innovation Cycle:

The Healthcare Innovation Cycle, Figure 1, parallels the US Department of Defense's well-established Technology Readiness Level (TRL) framework. It establishes a sequence of healthcare specific milestones that creates a roadmap to guide teams as they navigate the complex journey from an unmet clinical need to becoming the standard of care. However, it differs from the TRL framework in three important ways:

First, it represents the process as a cycle rather than being linear and starting with the technology. This highlights a key lesson learned: to improve the chances of success, start with unmet clinical needs/problems rather than technology solutions and always keep a focus on improving patient care and not become enamored with improving the technology. When done correctly, the cycle operates as a spiral, arriving at the end of each rotation at a higher standard of care, awaiting new medical insights and innovations for further enhancement.

Second, TRL's stop at 9, with the solution being used in practice and a 10<sup>th</sup> was added for healthcare. In healthcare,





considerable work is needed to disseminate innovations so that they are widely available. So, Healthcare Innovation Cycle has a 10<sup>th</sup> milestone: "Standard of Care".

Third, de-risking healthcare projects requires constantly balancing the perspectives from four key domains critical to creating a successful healthcare solution: clinical, market/business, regulatory, as well as technical. The TRL framework only focuses on the technology – why create a new product with nifty new technology that nobody wants to use or will by, and even if they wanted to, is not approved for use? We have found that proceeding in a balanced manner greatly assists teams in managing risks. Risks can never be eliminated, but they need to be understood and addressed as soon as possible so as not to reduce the chances of following a path that leads to a dead-end.

### **De-Risking**

Examples of the types of questions in the four domains that are addressed at each milestone are outlined below, with increasing evidence expected as the solution matures:

- Clinical Risk Will the innovation be accepted and adopted in a workflow and produce real improvements in outcomes and/or lower costs?
- Market/ Business Risk Is there a significant unmet need with enough buyers willing to buy the innovation at a sustainable price?
- Regulatory Risk What claims will you need to prove and how long/ how much will it cost to get approval?
- Technical Risk Will the technology be protectable as well as work better and be lower cost than alternatives?

### **Defining Deliverables**

CIMIT's experience is that while each is journey is different, just as each ascent a mountain climber makes on a new peak is different, the underlying disciplines applied are the same. To capture the experiences, it has defined a core set of deliverables for each milestone and domain that should be finished before advancing too far into the next milestone.

Attached is a table that has the core set of deliverables in each "cell" of the 4 domains by 10 milestones matrix for HealthTech solutions (in the EU). Check-off each Deliverable that is complete and use the Deliverables to plan your work – which in some cases will mean filling in gaps

### Guidance and Impact Tracking System (GAITS)

To assist teams and portfolio managers utilize the Healthcare Innovation Cycle, CIMIT developed and is piloting a secure, on-line platform: The GAITS platform. It provides descriptions of the deliverables at the intersection of each milestone and domain along with resources to help teams complete them. It is configured to reflect the differences in fields (e.g. HealthTech, Pharma, Health IT, etc.) and expectations of unique customers. (e.g. Military) The resources (e.g. descriptions, videos, templates, examples, etc.) are curated, peer-rated, and open source to present teams with the ones that are most effective in helping complete each deliverable.

The platform will also provide tracking, planning, reviewing, and reporting functions. A pilot is currently ongoing, and the platform is expected to be commercially available in the fall of 2018.

### Contact:

Please feel free to contact John Collins with questions or to learn more: jcollins11@mgh.harvard.edu



### Healthcare Innovation Cycle – HealthTech Deliverables Matrix (EU)

Solution Name: Date: Milestone Overall Clinical **Regulatory**/ Approvals **Market/Business** Technology Description Name Unmet needs □ Needs screening & Insights into unmet defined selection 1) Need clinical needs and NA NA Disease state available solutions Existing solutions characterized characterized Clinical workflow Paper Prototype Competitive Potential solutions description Medical device landscape Hvpothesis & to unmet need Updated need intended use 2) Idea experimental design developed and description Envisioned Value Equivalent devices evaluated □ Idea screening & □ Feedback from >5 Proposition identified selection clinicians Competing solutions Preliminary Feedback from Key component characterization PoC prototypes classification clinicians in >5concepts validated Preliminary Value 3) Proof of Demonstration settings Preliminary intended in models and Concept Proposition results value proposition Updated need use (PoC) Path to Payment Institutional IP articulated description and Preliminary plan disclosure workflow regulatory pathway Stakeholder Map "Works Like" & Draft Essential Feasibility of Feedback from "Looks Like"  $\Box$  Feedback from >5 Requirements whole solution clinicians in >20prototypes economic buyers Checklist 4) Proof of demonstrated in settings Freedom to operate Feasibility Impact Plan (draft Draft Instructions for models and in Updated need & (PoF) review business plan) feedback from use workflow stakeholders Provisional IP filing Advisory Board Institutional approval descriptions request(s) Killer Experiment



# Healthcare Innovation Cycle – HealthTech Deliverables Matrix (EU)

Milestone Name	Overall Description	Clinical	Market/Business	Regulatory/ Approvals	Technology
5) Proof of Value (PoV)	The potential of the solution to work and create value for all stakeholders is demonstrated (Initial commercial investment)	<ul> <li>Feedback from &gt;100 clinicians and KOLs</li> <li>Animal/First-in- Man experiments</li> <li>Peer reviewed publication(s)</li> <li>Scientific Advisory Board</li> </ul>	<ul> <li>Investor ready business plan</li> <li>Feedback from &gt;20 economic buyers</li> <li>Key management team identified</li> <li>Initial seed investment</li> </ul>	<ul> <li>Application form to national competent authority</li> <li>Data requirements</li> <li>Clinical Investigation approval(s)</li> </ul>	<ul> <li>"Works Like/Looks Like" prototypes</li> <li>BOM, manufacturing plan, and costing</li> <li>Full IP application</li> <li>Killer technical experiment</li> </ul>
6) Initial Clinical Trials (ICT)	Regulated production of prototypes and collection of clinical and economic data	<ul> <li>Conduct Phase 0 and/or 1 clinical trial(s)</li> <li>Peer reviewed publication(s)</li> </ul>	<ul> <li>Economic data</li> <li>Feedback from &gt;50 economic buyers</li> <li>1st Institutional Investment</li> </ul>	<ul> <li>Data requirements confirmation</li> <li>Pre-submission</li> </ul>	Manufacture GMP- compliant pilot lots.
7) Validation of Solution (VoS)	The solution is shown to be effective and its value to all stakeholders is validated	<ul> <li>Clinical efficacy trials</li> <li>Peer reviewed publication(s)</li> </ul>	<ul> <li>Purchasing intent from &gt;10 buyers</li> <li>2nd round of institutional investment</li> </ul>	<ul> <li>Complete Technical File</li> <li>Technical File submission to Notified Body (CE Mark)</li> </ul>	GMP Process Planning
8) Approval & Launch (A&L)	Institutional and regulatory approval received, and sales launched	<ul> <li>Training materials &amp; support established</li> <li>Peer reviewed publication(s)</li> </ul>	☐ Initial sales	<ul> <li>Registration and Listing (CE mark)</li> <li>CMS Coverage &amp; CPT Code Determination</li> </ul>	☐ Finalized GMP process



# Healthcare Innovation Cycle – HealthTech Deliverables Matrix (EU)

Milestone Name	Overall Description	Clinical	Market/Business	Regulatory/ Approvals	Technology
9) Clinical Use (Use)	The solution is used successfully in day-day clinical practice	<ul> <li>Included in local practice guidelines</li> <li>Peer reviewed publication(s)</li> </ul>	Profitable sales	Monitoring and Inspections	<ul> <li>Patents issued</li> <li>Improvement plan</li> </ul>
10) Standard of Care (SoC)	The solution is recognized as the Standard of Care.	Recommended practice by medical specialty	Dominant market share	NA	NA